Onyvax Limited
Records under this name other than patents Onyvax Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 7 of 7 · Back to Onyvax Limited
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,097,244 | Human prostate cell lines in cancer treatment Lapsed on the fee record Ended Jan 17, 2024 · From the USPTO record | Lapsed on the fee record | Ended Jan 17, 2024 | From the USPTO record |
| US 7,438,922 | Human prostate cell lines in cancer treatment Term ended Term ended Oct 27, 2023 · From the USPTO record | Term ended | Term ended Oct 27, 2023 | From the USPTO record |
| US 8,545,835 | Human prostate cell lines in cancer treatment Lapsed on the fee record Ended Oct 1, 2021 · From the USPTO record | Lapsed on the fee record | Ended Oct 1, 2021 | From the USPTO record |
| US 6,699,483 | Cancer treatments Term ended Term ended Sep 7, 2021 · From the USPTO record | Term ended | Term ended Sep 7, 2021 | From the USPTO record |
| US 6,972,128 | Use of human prostrate cell lines in prostate cancer treatment Term ended Term ended Dec 9, 2019 · From the USPTO record | Term ended | Term ended Dec 9, 2019 | From the USPTO record |
| US 7,303,911 | Prostate cell lines Lapsed on the fee record Ended Dec 4, 2019 · From the USPTO record | Lapsed on the fee record | Ended Dec 4, 2019 | From the USPTO record |
| US 8,034,360 | Use of human prostate cell lines in cancer treatment Lapsed on the fee record Ended Oct 11, 2019 · From the USPTO record | Lapsed on the fee record | Ended Oct 11, 2019 | From the USPTO record |